XOMA CC addendum: A Gevokizumab BLA based on EYEGUARD-B only* would have only a Behçet’s indication rather than a general NIU indication. Since the Behçet’s prevalence is many times smaller than the general NIU prevalence, a Behçet’s-only indication would require that Gevokicumab carry a very high price to produce commercially meaningful sales.
*The backup plan mentioned for the first time on today’s CC.
I suspect the biggest impediment to filing based only on EYEGUARD-B is likely to be that all(!) of the Behcets data is ex-US. EYEGUARD-B isn't even enrolling in the US and all the ph ii is ex-US.
Market Data 
Markets 
AI
